Difference between revisions of "Temozolomide (Temodar)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Sarcoma" to "[[Category:Soft tissue sarcoma") |
||
| Line 44: | Line 44: | ||
[[Category:Myelodysplastic syndrome medications]] | [[Category:Myelodysplastic syndrome medications]] | ||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
| − | [[Category: | + | [[Category:Soft tissue sarcoma medications]] |
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
[[Category:Drugs FDA approved in 1999]] | [[Category:Drugs FDA approved in 1999]] | ||
Revision as of 02:58, 24 October 2017
Also known as Temcad and Temodal.
General information
Class/mechanism: Alkylator. Temozolomide is converted in vivo to the reactive compound 5-(3-methyltriazen-
1-yl)-imidazole-4-carboxamide (MTIC). MTIC causes alkylation of DNA at the O6 and N7 positions of guanine, leading to cell damage and cell death.[1][2][3]
Route: PO, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Bone cancer
- Central nervous system (CNS) cancer
- CNS lymphoma
- Melanoma
- Myelodysplastic syndrome
- Neuroendocrine tumors
- Sarcoma
- Small cell lung cancer
Patient drug information
- Temozolomide (Temodar) patient drug information from manufacturer[4]
- Temozolomide (Temodar) patient drug information (Chemocare)[5]
- Temozolomide (Temodar) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 8/11/1999: Initial FDA approval
References
- ↑ 1.0 1.1 Temozolomide (Temodar) package insert
- ↑ Temozolomide (Temodar) package insert (locally hosted backup)
- ↑ Temodar manufacturer's website
- ↑ Temozolomide (Temodar) patient drug information from manufacturer
- ↑ Temozolomide (Temodar) patient drug information (Chemocare)
- ↑ Temozolomide (Temodar) patient drug information (UpToDate)
- Drug index
- Chemotherapy
- Intravenous medications
- Oral medications
- Alkylating agents
- Acute myeloid leukemia medications
- Bone cancer medications
- Central nervous system (CNS) cancer medications
- Central nervous system (CNS) lymphoma medications
- Melanoma medications
- Myelodysplastic syndrome medications
- Neuroendocrine tumor medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Drugs FDA approved in 1999